ArticleACS omega2026
Biofabricated Alginate Hydrogels to Study Prostate Tumoral Microenvironments In Vitro.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered three-dimensional (3D) in vitro models are essential for recapitulating the human tumor microenvironment (TME) and deciphering the complex cell-material interactions driving cancer progression. This study presents the development of a prostate-specific bioprinted model designed to mimic both the biomechanical (stiffness) and biochemical (laminin-enriched) traits of the prostate cancer (PCa) extracellular matrix (ECM). We synthesized functionalized alginate hydrogels modified with laminin-mimetic peptides (IKVAV, AG73) and tuned their mechanical properties (2-20 kPa) to match the transition from healthy tissue to advanced/metastatic disease. Functionalized alginate hydrogel precursors were compatible with extrusion-based bioprinting and used to replicate TME heterogeneity by 3D bioprinting in vitro models containing PC-3 cells and cancer-associated fibroblasts (CAFs). PC-3 cells cocultured with cancer-associated fibroblasts (CAFs) within these hydrogels supported high cell viability and proliferation. Notably, phenotypic analysis revealed that stiffer, laminin-enriched matrices significantly upregulated the expression of CD44 and the epithelial-to-mesenchymal transition (EMT) marker vimentin in PC-3 cells. Interestingly, these matrix-driven effects were dominant, independent of the CAF presence within the observed window. This work establishes a robust, scalable biofabrication strategy for generating TME-mimetic models, offering a valuable tool for future studies in screening TME-targeting therapies and investigating the mechanobiology of PCa progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.